Clophelin tablets

Quick links to important sections

Clophelin tablets

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clophelin tablets

Quick Facts

Property Description
Active ingredient Clonidine (INN)
Form Tablets (Oral Dosage Form)
Pharmacological class Centrally Acting Antihypertensive Agent
Common use Reducing elevated blood pressure
Origin Synthetic (Imidazoline derivative)

The Core Identity and Classification of Clophelin Tablets

Clophelin tablets are a prescription-only medication primarily classified as a centrally acting antihypertensive agent, defined by its sole active ingredient, Clonidine (INN). The pharmacological classification places it within the sympatholytic agent class, characterizing its mechanism on the nervous system. This classification is key to understanding its therapeutic profile, as it acts on the central nervous system to control blood pressure, setting it apart from agents that work exclusively in the periphery.

Composition, Origin, and Dosage Form

The drug is supplied as an oral dosage form, specifically tablets, which are designed for systemic absorption following ingestion. The active ingredient, Clonidine, is a synthetic compound structurally known as an imidazoline derivative. While Clophelin is a specific brand name, the Clonidine formulation is internationally recognized, commonly marketed under brands such as Catapres and Dixarit in other regions, which share the same core active ingredient and general use. The tablets are a single active ingredient product, consisting only of Clonidine combined with necessary excipients.

General Purpose and Systemic Action

The overarching general purpose of Clophelin tablets is to support the cardiovascular system by achieving a sustained lowering of blood pressure. This therapeutic goal is clinically recognized for managing patients with elevated blood pressure when a central regulatory approach is required. The drug accomplishes this through its central sympatholytic action, a mechanism where it reduces the overall sympathetic outflow from the brain. By diminishing the signals that constrict blood vessels and accelerate the heart, the medication effectively lessens the resistance to blood flow.

What side effects are possible with Clophelin tablets?

Possible side effects and safety information

Clophelin (Clonidine) tablets are associated with adverse reactions that regulatory documents classify by frequency and the body systems affected, primarily involving the central nervous system and cardiovascular function. Understanding this classification is essential to the medicine's safety profile.

Adverse reactions that are formally classified as Very Common (affecting more than 1 in 10 individuals) include dry mouth (xerostomia) and sedation (somnolence). Effects designated as Common include dizziness, headache, fatigue, nausea, vomiting, constipation, depression, and orthostatic hypotension (a drop in blood pressure upon standing). Uncommon reactions may include bradycardia (slow heart rate), rash, and hallucinations, while rare documented effects include gynecomastia and alopecia.

Regulatory labels highlight specific safety concerns. The most significant is the potential for rebound hypertension—a rapid, potentially severe rise in blood pressure—which is explicitly documented to occur if the medication is stopped suddenly after prolonged use. This phenomenon is a critical factor in the drug's safety handling.

Safety notes for specific groups are also defined. For older adults and individuals with renal impairment, regulatory documents advise caution and may require a lower initial dose and careful observation due to the medicine's impact on blood pressure and heart rate. Furthermore, Clonidine may potentiate the sedative effects of other central nervous system depressants. These classifications reflect the mandated observation requirements and risks documented by government health authorities.

Overdose and Emergency Response

Overdose and when to Seek Help

The official regulatory profile for Clophelin tablets (Clonidine) overdose is centered on severe depression of the central nervous system (CNS) and significant cardiovascular collapse. Overdose is characterized by manifestations such as profound somnolence, lethargy, and miosis (pinpoint pupils), often progressing to states of stupor or coma. Documented physiological signs include severe hypotension (low blood pressure), marked bradycardia (slowed heart rate), and hypothermia, along with occasional reports of vomiting.

Overdose can lead to life-threatening outcomes, specifically respiratory arrest, severe cardiac conduction defects, and circulatory collapse. Due to the potential for delayed and prolonged toxicity, immediate medical attention is required for any suspected overdose. Regulator guidance mandates that patients receive emergency medical care and hospital monitoring.

Management is defined as symptomatic and supportive treatment, as no specific antidote is known. Official procedures documented for managing the resulting clinical state include the use of Atropine for symptomatic bradycardia and vasopressor agents for persistent, severe hypotension. Regulatory documents also note that the pediatric population is highly susceptible, with even small doses potentially resulting in significant toxicity.

Therapeutic Uses of Clophelin tablets

What Clophelin Tablets Treats: Main Uses and Benefits

Clophelin tablets (Clonidine) are primarily used in situations involving certain distressing symptoms related to systemic imbalance and heightened physiological activity. Its most common application is the management of high blood pressure (hypertension), a condition where symptoms are often linked to increased physiological stress.

Clophelin is commonly used in conditions characterized by periods of heightened symptoms and where supportive symptom management is appropriate. It is applied across several therapeutic areas, including the lowering of high blood pressure; is relevant for managing symptoms of certain neurobehavioral disorders (such as ADHD and Tourette Syndrome); may assist with acute substance withdrawal symptoms; and is considered relevant as an adjunct therapy for severe, chronic pain.

“It is applied in clinical settings that involve acute or unstable symptom patterns and situations involving recurrent or episodic manifestations.”

The medication is commonly used to help with symptoms that create noticeable physiological strain. By managing these manifestations, it provides support that may help ease the overall symptom burden and contributes to improved comfort during symptomatic periods.

Quick Fact: Relief for Key Symptoms
Primary Focus Elevated Blood Pressure, Autonomic Symptoms
Neurobehavioral Hyperactivity, Impulsivity, Motor/Vocal Tics
Acute Support Physical Distress from Opioid/Alcohol Withdrawal

Regulatory References

  1. NIH MedlinePlus overview on Clonidine

Eligibility and Restrictions for Use

Who Can and Cannot Use Clophelin Tablets?

The population eligibility for Clophelin tablets (Clonidine) is strictly defined by government regulatory documents, focusing on absolute exclusions, conditional restrictions, and age limitations.

Absolute Non-Eligibility (Contraindications)

Patients who must not use this medication include those with a known hypersensitivity to Clonidine or any of the inactive ingredients. It is also contraindicated for individuals experiencing severe bradyarrhythmia resulting from conditions such as sick sinus syndrome or Atrioventricular (AV) block of 2nd or 3rd degree.

Conditional and Age-Related Restrictions

Clophelin tablets are officially allowed for use in adults for managing high blood pressure. However, use is generally not recommended for children and adolescents under 18 years for this primary indication, as safety and efficacy have not been established in this age group.

Use is restricted and requires careful consideration in populations with compromised organ function, such as those with chronic renal failure or renal insufficiency. Caution is also required for patients with pre-existing cardiovascular conditions, including severe coronary insufficiency and recent myocardial infarction.

Reproductive Status

Use during pregnancy is generally advised only if considered essential by a healthcare provider. The medication is not recommended for mothers who are breastfeeding, as the active substance is known to be excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Clophelin (Clonidine) has documented interactions that are primarily pharmacodynamic, meaning they involve combined effects on the central nervous and cardiovascular systems as described in official regulatory prescribing information.

Documented Interaction Patterns

Classification Interacting Agents / Classes Official Regulatory Concern
Potentiation CNS Depressants (including alcohol) Risk of additive sedative effects and CNS depression.
Cardiovascular Effects Beta-blockers, Digitalis, Calcium Channel Blockers Risk of additive effects leading to bradycardia and AV block.
Antagonism Tricyclic Antidepressants (TCAs) May reduce or abolish the blood pressure-lowering effect.
Hypotensive Increase Other Antihypertensive Agents Potential for increased blood pressure reduction.

Official Constraints and Restrictions

Co-administration with other Clonidine-containing products is restricted to prevent over-exposure. The official profile notes that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce Clophelin's therapeutic effectiveness.

A specific procedural requirement exists for discontinuation: if Clophelin and a beta-blocker are both being stopped, the beta-blocker must be gradually withdrawn over several days before the gradual discontinuation of Clophelin. This procedural rule manages the risk of rebound hypertension.

Mechanism of Action

The function of Clophelin (Clonidine) is defined by its action as an agonist primarily targeting the central nervous system (CNS), where it engages mechanisms that regulate physiological processes.

Central Sympathetic Braking via Alpha-2 Receptor Agonism

Clophelin tablets exert their principal effect by acting on presynaptic alpha-2 (alpha2) adrenergic receptors within the brainstem's vasomotor center. This interaction is coupled to an inhibitory Gi protein cascade, initiating an autoinhibitory signal that reduces the release of the neurotransmitter norepinephrine (noradrenaline) from central nerve endings. This reduction in the body's primary sympathetic excitory mediator modifies early molecular steps that shape systemic physiological effects.

Regulation of Vascular Tone and Cardiac Activity

The central reduction of norepinephrine signaling leads to a profound diminution of sympathetic outflow from the CNS to the periphery, affecting systems where specific transmitters dominate. This modification of the autonomic tone produces two physiological effects: it promotes vasodilation (widening of peripheral blood vessels) and causes bradycardia (slowing of the heart rate). This cascade produces predictable physiological adjustments which affect arterial blood pressure.

Mechanistic Constraints and Adaptive Responses

The mechanism is not without functional constraints. While the drug is primarily central, initial absorption can cause a transient activation of peripheral alpha2 receptors, leading to a temporary and slight peripheral vasoconstriction. Furthermore, chronic use engages feedback regulation within pathways, causing receptor adaptation; if the drug is stopped suddenly, this adaptation results in an unchecked surge of norepinephrine, which underlies the mechanism of rebound hypertension.

Dosage and Administration Information

How to Use Clophelin Tablets: Administration Guidelines

Clophelin (Clonidine immediate-release tablets) is administered via the oral route, following established dosing and scheduling patterns. For adults, treatment is typically initiated with a low daily dose, such as 0.1 mg per day, which is commonly administered in two divided doses.

Dosing and Titration Protocol

The goal is to reach a maintenance dose, usually ranging from 0.2 mg to 0.6 mg per day, while adhering to the maximum recommended daily dose of 2.4 mg. Dose adjustments are to be gradual, occurring in small increments of no more than 0.1 mg per day, and added at weekly intervals.

Administration Scope Details
Route of Administration Oral (by mouth) for the tablet formulation.
Dosing Schedule (Maintenance) Typically 0.2 mg to 0.6 mg per day in divided doses.
Timing in Relation to Meals May be taken with or without food.

Administration Conditions and Course Management

When the total daily dose is divided, it is often suggested to take the larger portion of the dose at bedtime. This drug is not to be stopped suddenly; a controlled discontinuation procedure is required. The dose must be tapered gradually in decrements of no more than 0.1 mg every three to seven days, and must not be discontinued abruptly. Furthermore, patients with renal impairment or older adults may require a lower initial dose and a slower titration schedule. The immediate-release tablets may be cut in half for dose flexibility in some regions, such as the 100 microgram tablet providing a 50 microgram dose.

Recent Clinical Evidence

Research Evidence for Managing High Blood Pressure

Research has explored the use of Clophelin (Clonidine) tablets for conditions involving physiological strain or stress, primarily focusing on elevated blood pressure (hypertension). Research for this use has involved short-term Randomized Controlled Trials (RCTs) and active-comparator studies, often applied in research contexts involving fluctuating or unstable symptoms. These trials primarily included adults with mild-to-moderate hypertension and those with certain cases of resistant blood pressure.

Research examined blood pressure levels (systolic and diastolic) and how they evolved over defined time intervals following administration. Numerous reports over several decades describe measured changes in these outcomes in the observed populations. This evidence base is long-standing, contributing to the broader evidence landscape for antihypertensive agents.


Studies Exploring Symptoms in Acute Withdrawal

The agent was studied for conditions associated with acute or disruptive episodes, specifically the physical discomfort during opioid or alcohol withdrawal. The research primarily consisted of short-term RCTs and systematic reviews focused on populations of adults undergoing monitored withdrawal.

Studies monitored outcomes related to physiological strain or stress, such as elevated heart rate, tremor, and sweating. Trials frequently described patterns related to measured changes in autonomic signs of distress across the acute withdrawal period.

However, the evidence is mostly confined to the acute detoxification phase, with follow-up durations being limited. This means there is limited information on extended-duration outcomes following the acute phase. Furthermore, data for certain groups remain insufficient, and evidence quality varies across these specific studies.


Evidence for Neurobehavioral Symptom Control

The agent was evaluated in studies exploring patient-reported outcomes in conditions characterized by fluctuating or episodic manifestations, such as Attention-Deficit/Hyperactivity Disorder (ADHD) and Tourette Syndrome/Tic Disorders. Short-duration RCTs and meta-analyses were conducted, primarily in populations of children and adolescents.

Studies monitored how symptoms evolved in the observed populations, and research highlighted changes measured in scale scores for hyperactivity, impulsivity, and tic severity. Generally, long-term effects are not fully established, and follow-up durations were limited for these studies, indicating uncertainty about extended functional measures.

Key Studies & References

  1. NICE Guideline: Hypertension in adults: diagnosis and management (NG136)

Frequently Asked Questions (FAQ)

Common questions about Clophelin tablets (FAQ)

Q: How quickly does Clophelin start lowering blood pressure after taking a tablet?

According to regulatory pharmacokinetic data, the blood pressure-lowering effect of Clophelin typically begins within 30 to 60 minutes after taking an oral tablet. The maximum observed decrease in blood pressure typically occurs within 2 to 4 hours, according to clinical data.

Q: How long does the effect of a single Clophelin dose usually last?

Official regulatory data notes that the elimination half-life of the active ingredient (Clonidine) ranges from 12 to 16 hours in people with normal kidney function. The half-life describes the time it takes for half of the medicine to be cleared from the body.

Q: What foods or drinks need to be avoided while taking Clophelin?

The official product information states that food does not affect how the tablet is absorbed, meaning it can be taken with or without a meal. However, official information suggests avoiding alcohol while on this medication, as it can increase the sedative effects of Clophelin.

Q: Is it okay to take common pain relievers (like ibuprofen) with Clophelin?

Official drug interaction information notes that certain non-prescription pain relievers, specifically a class known as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), may interfere with Clophelin. These NSAIDs are noted to potentially reduce the blood pressure-lowering effect of the medication.

Q: Why is it important to check my blood pressure and heart rate regularly while on this medicine?

It is important to monitor heart rate and blood pressure regularly because Clophelin can cause dose-related decreases in both measures. Regulatory documents state that these checks must be performed before starting therapy, after any dose changes, and periodically throughout treatment to monitor the drug's effect and support dose adjustments.

Q: Is it safe to drive or operate heavy machinery when taking Clophelin?

Due to the potential for common side effects like sedation, dizziness, or vision changes, official patient information advises caution. Official safety information cautions against operating heavy equipment or driving until a patient knows how they respond to the treatment.

Q: Why is Clophelin sometimes used before or after surgery?

The administration of Clophelin tablets is generally advised to be continued up to four hours prior to surgery and then resumed as soon as possible afterward, while blood pressure is closely monitored. This information is based on official prescribing documents regarding perioperative use.

Q: Why is Clophelin prescribed for problems other than blood pressure, such as ADHD or certain pain conditions?

Clophelin’s function involves acting on the central nervous system to reduce sympathetic outflow (the nerve signals that typically increase heart rate and blood pressure). This central action is thought to influence various physiological processes, which underlies its approved uses for conditions like ADHD.

Q: Will taking Clophelin cause me to gain weight?

Official regulatory documents list weight gain as a potential adverse reaction reported in postmarketing experience. However, it is not classified in the official label as one of the common or very common side effects of the medication.

Q: Does Clophelin affect sexual function or cause related changes?

Adverse reactions reported during postmarketing surveillance indicate that Clophelin may affect sexual function. These effects have included decreased libido (sexual desire) and impotence (difficulty achieving or maintaining an erection).

Q: Is it normal to have nightmares or vivid dreams with Clophelin?

Official safety labels indicate that difficulty sleeping (insomnia) is a reported side effect of the medication. Additionally, vivid dreams or nightmares have been reported rarely in the postmarketing surveillance experience.

Q: Are there common side effects that usually improve or go away over time?

While side effects like dry mouth and drowsiness are noted, official prescribing information suggests these may be transient adjustment effects. The prescribing information often suggests taking the larger portion of the dose at bedtime to help minimize these specific effects.

Q: Is Clophelin known to cause dependence or physical need if taken long-term?

Clophelin is not classified as a controlled substance and has a limited potential for abuse, according to official classifications. However, long-term use can lead to a state of physical dependence, which is why abrupt discontinuation is strictly prohibited due to the risk of rebound hypertension.

Q: Does Clophelin affect sleep or cause insomnia?

The official list of adverse reactions includes insomnia, which is defined as difficulty falling or staying asleep. This is listed as an adverse reaction in the postmarketing experience section of the official label.

Q: Why is it important to be careful with Clophelin in hot weather or during strenuous exercise?

Patients who may be prone to sudden loss of consciousness (syncope), such as those with low blood pressure, are advised to take precautions. The regulatory warnings indicate that patients should be cautious about situations that may cause dehydration or overheating.

Q: Why do official documents mention colonic pseudo-obstruction as a rare side effect?

The drug's mechanism of reducing sympathetic activity can affect the natural movement (motility) of the gut, and this condition has been rarely reported in postmarketing experience.

How should Clophelin tablets be stored and disposed of?

Clophelin Tablet Storage and Disposal

The storage of Clophelin tablets (clonidine) is strictly defined by regulatory requirements to ensure product integrity. The medicine must be kept at Controlled Room Temperature, specifically between 20 to 25 C (68 to 77 F), with excursions limited to 15 to 30 C.


Storage Constraints

The tablets must be protected from light and stored in the tightly closed original container. It is explicitly required that Clophelin tablets are not refrigerated or frozen. For safety, the medicine must be stored out of the reach of children and secured [1].

Official Disposal

Disposal must adhere to pharmaceutical waste guidelines. Unused or expired tablets should be returned via an authorized drug take-back program. The product must not be flushed down a drain. If no take-back option is available, the medicine should be mixed with an unappealing material, sealed, and placed into household trash [2].

[1] Official Regulatory Labeling (e.g., FDA, EMA SmPC) [2] US FDA Medicine Disposal Guidance

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clophelin tablets found in:

A-Z Index: